Noticias de PFE_US
Noticias del mercado
Últimas noticias sobre PFE_US — 665 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Novartis India will acquire trademarks registered in India and certain related intellectual property rights for Rs 1,250 crore
The company has executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc USA and Pfizer Products Inc USA
Novartis India will acquire the trademarks and intellectual property rights of Minipress, Pfizer’s hypertension drug, for ₹1,250 crore in a deal approved on September 7.
Novartis India acquires Minipress brand from Pfizer for ₹1,250 crore. Learn about the deal details, brand revenue, valuation, and potential risks for investors.
Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore. Minipress XL, used for hypertension and benign prostatic hyperplasia, generated ₹228.6 crore in revenue as of July 2026, according to IQVIA data.
Pfizer Limited ends Minipress XL sale operations, receives USD 13.9 million payout from Pfizer Inc. USA post manufacturing halt.
Novartis India said its board approved the transaction at a meeting held on September 7. The company subsequently executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc. and Pfizer Products Inc. USA.
Novartis India will acquire Pfizer’s Minipress and Minipres brands for Rs 1,250 crore as Pfizer stops selling the hypertension medicine in India.
Novartis India acquires BP drug trademarks from Pfizer for ₹1,250 crore, following ChrysCapital's stake acquisition.
Pfizer Limited will stop selling Minipress XL on Sept 7, 2026, following its parent company's decision to halt manufacturing. Pfizer Limited will receive a $13.9 million payment.
Pfizer said on Monday that it will discontinue the marketing, distribution and sale of Minipress XL in India with effect from September 7, 2026.
Pfizer Limited is immediately discontinuing the marketing, distribution, and sale of Minipress XL in India due to global manufacturing cessation by Pfizer Inc.
Novartis India acquires Minipress and Minipres trademarks from Pfizer. Total consideration for the deal stands at ₹1,250.001 crore. Board approved the transaction on September 7, 2026. Minipress XL generated ₹228.6 crore revenue as per July 2026 data.
Pfizer Limited discontinues Minipress XL sales effective September 7, 2026. Decision follows Pfizer Inc. USA halting manufacture of the product. Company to receive $13.9 million (~₹131.38 crore) lump sum payment. Transaction approved by Board of Directors in meeting on September 7, 2026.
Pfizer Ltd to discontinue Minipress XL from Sept 2026. Company to receive Rs 131.38 crore one-time compensation from parent Pfizer Inc. USA.
Página 29 de 34